PET-CT scan compares two tests for lung scarring
Part of Lungs & breathing clinical trials.
This early (Phase 1) study compares two types of PET-CT scans to see how well they detect and measure lung scarring (pulmonary fibrosis). It may help doctors choose the best scan test for diagnosis in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have suspected or confirmed lung scarring (pulmonary fibrosis)
- You can sign a written consent form to join the study
- You are not pregnant
- You are not breastfeeding
- You do not have a known allergy to FAPI (the scan material)
- No other medical issue that could make it hard for you to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a special PET scan that uses a new tracer to help see fibrosis (scarring) in the body. It may help doctors better understand and manage conditions like lung or liver fibrosis.
This study uses a special PET scan (called FAPI-74) to see if it can detect fibrosis (scarring) in the lungs of people with active TB. It looks at the scan both at the start of treatment and after 6 months of therapy to understand how the lungs heal.
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
This trial is testing a new type of PET scan (FAPI PET) to help doctors see if lung scarring (fibrosis) is getting worse or getting better. It may help decide if a treatment change is needed.
This trial is testing a new type of PET scan that may help see lung cancer more clearly. It could help doctors understand your cancer better and plan the best treatment.
This Phase 1 study tests a specialized imaging agent that can help show differences (heterogeneity) in lung scarring in idiopathic pulmonary fibrosis (IPF). It’s mainly about safety and whether the imaging works for people with certain genetic and lung-function features.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.